

Ovarian Cancer (Epithelial) Pathways

Patient Name: _____

Date of Birth: _____

Member Number: _____

Treatment Start Date: _____

Pathology: _____

Stage: _____

Line of Therapy: __Neoadjuvant/Pre-Op __Adjuvant/Post-Op
__1st Line __2nd Line __3rd Line __3rd Line+ __Maintenance

ECOG Performance Status: _____ **ICD-10 Code:** _____

Biomarkers/Characteristics: (Select all that apply)

BRCA1 Status: __Germline Mutation __Wild Type (no mutation)
__Somatic Mutation __Not Reported

Platinum Sensitive*: __Yes __No __Not Reported

Platinum Refractory/Resistant: __Yes __No __Not Reported

BRCA2 Status: __Germline Mutation __Wild Type (no mutation)
__Somatic Mutation __Not Reported

Adjuvant Therapy | Stage IA/B (Grade 2 or 3) or IC (Grade 1-3)

- Carboplatin and dose dense paclitaxel
- Carboplatin and paclitaxel

Adjuvant or Primary Therapy | Stage II, III, IV

- Carboplatin and paclitaxel (**Administered weekly or every 3 weeks**)
- Intravenous (IV) paclitaxel and Intraperitoneal (IP) cisplatin and IP paclitaxel (**Stage III only**)

Recurrent Disease | First and Subsequent Lines of Therapy (1st Line+) | Platinum-Sensitive*

- Carboplatin
- Carboplatin and gemcitabine (Gemzar)
- Carboplatin and paclitaxel
- Carboplatin and weekly paclitaxel

Recurrent Disease | Maintenance Therapy | Platinum-Sensitive*

- Niraparib (Zejula)

Recurrent Disease | Second and Subsequent Lines of Therapy (2nd Line+) | Platinum Resistant

- Bevacizumab (Avastin) monotherapy
- Docetaxel (Taxotere)
- Gemcitabine (Gemzar)
- Liposomal doxorubicin (Doxil or Lipodox)
- Paclitaxel (weekly)
- Paclitaxel and bevacizumab (Avastin)
- Tamoxifen
- Topotecan (Hycamtin)
- Topotecan (Hycamtin) and bevacizumab (Avastin)
- Vinorelbine (Navelbine)

*Platinum sensitive disease is defined as recurrence of greater than 6 months after prior platinum-based therapy

Note: Pathway lists are solely for the purpose of eligibility for enhanced reimbursement and are independent of specific health plan medical policy coverage criteria. Health plan medical policy/clinical guidelines should be consulted to determine whether proposed services will be covered.

